Analyst Clémence Thiers from Stifel Nicolaus maintained a Buy rating on MaaT Pharma (MAAT – Research Report) and keeping the price target at €22.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Clémence Thiers has given his Buy rating due to a combination of factors that highlight MaaT Pharma’s promising developments and future potential. The company has recently received a positive opinion from the EMA Pediatric Committee for its Pediatric Investigation Plan, which is a significant regulatory milestone. This approval allows MaaT Pharma to proceed with clinical evaluations of MaaT013 in pediatric patients, indicating a strong commitment to addressing unmet medical needs in aGvHD.
Moreover, the successful results from the ARES P3 trial, demonstrating significant efficacy and survival rates, bolster confidence in MaaT013’s potential market success. With plans to submit a Marketing Authorisation Application to the EMA by mid-2025, MaaT Pharma is on track for regulatory approval by 2026. Despite the need for additional funding to extend its cash position, the company’s strategic advancements and potential peak sales projections make it an attractive investment opportunity.
According to TipRanks, Thiers is ranked #9083 out of 9347 analysts.